CMP
NVO

Coston McIsaac & Partners’s Novo Nordisk NVO Stock Holding History

Coston McIsaac & Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Hold
40
– – ﹤0.01% 796
2025
Q4 		$2K Buy
+40
New +$2.04K ﹤0.01% 749

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Coston McIsaac & Partners's NVO Position: Q1 2026 in Review

Coston McIsaac & Partners held its Novo Nordisk (NVO) position steady in Q1 2026 at 40 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #796.

Coston McIsaac & Partners first reported a position in NVO in Q4 2025 and has held it in 2 quarters since. The position peaked at $2K in Q4 2025. 1,274 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Coston McIsaac & Partners held 40 shares of Novo Nordisk worth $1K as of Q1 2026.
  • Coston McIsaac & Partners left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q1 2026, its #796 holding.
  • Coston McIsaac & Partners first reported a position in Novo Nordisk in Q4 2025 and has held it in 2 quarters since.
  • Coston McIsaac & Partners's Novo Nordisk position peaked at $2K in Q4 2025.
  • 1,274 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Coston McIsaac & Partners's 13F filing for Q1 2026, filed 22 Apr 2026.